NCT03486366 (EPIMARKER) is a NA clinical trial of non interventional trial in Epilepsy, sponsored by Medical University of Warsaw.

Who is sponsoring NCT03486366?

NCT03486366 is sponsored by Medical University of Warsaw.

What drugs are being tested in NCT03486366?

Interventions in NCT03486366: non interventional trial.

Is NCT03486366 still recruiting?

NCT03486366 is currently status unknown. Last updated 3 April 2018.

Last reviewed 2018-04-03 · How we verify

NCT03486366: EPIMARKER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children.

Status unknown NA Last updated 3 April 2018

What this trial tests

NA trial testing non interventional trial in Epilepsy in 120 participants. Status unknown.

Timeline

1 April 2017

Primary endpoint
30 March 2020

30 March 2020

Quick facts

Lead sponsor	Medical University of Warsaw
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	120
Start date	1 April 2017
Primary completion	30 March 2020
Estimated completion	30 March 2020
Sites	1 location across Poland

Drugs / interventions tested

non interventional trial

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Medical University of Warsaw

Who can join

Adults 1 Day to 16, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Epilepsy affects 1% of the world's population and 6 million people in Europe. The estimated total cost of €20 billion in Europe in 2014 makes epilepsy a significant socioeconomic burden. Despite great progress in the management of epilepsy and increasing numbers of antiepileptic drugs, 30-40% of epilepsy patients are refractory to all available medications. Moreover, in childhood epilepsy is a causative factor of psychiatric and behavioral comorbidities, including developmental delay and autism spectrum disorder. In spite of multiple trials no reliable biomarker of epilepsy development has been identified. There are no studies on biomarkers of drug-resistance or epilepsy recurrence after the drug withdrawal. EPIMARKER is a first project, carried out in humans, which is going to examine in prospective way clinical, electroencephalographic and molecular biomarkers to produce an integrative tool useful in everyday diagnosis and treatment of epilepsy in children to prevent the development of drug-resistant epilepsy and its behavioral comorbidities as mental retardation and autism. The set of molecular biomarkers will be determined by quantitative transcriptomic and proteomic studies and validated in reprogrammed cellular models.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024).
Aliashrafzadeh H, Liu D, De Alba S, Akbar I, et al · · 2025 · PMID 40708570 · DOI 10.37349/eds.2025.1008116

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Medical University of Warsaw trials

Trials by the same sponsor.

NCT07515768 — TAVI Without On-Site Cardiac Surgery in Poland: A Randomized Multicenter Trial Protocol · NA · not yet recruiting
NCT07511907 — Routine Intraoperative White Test for Bile Leak Detection in Liver Resection · NA · not yet recruiting
NCT07498660 — PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomize · NA · not yet recruiting
NCT07398898 — Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients · NA · recruiting
NCT07237204 — 15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03486366 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Warsaw
Last refreshed: 3 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03486366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing